Aptevo Therapeutics, Inc.
(NASDAQ : APVO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.74%306.720.0%$5256.57m
BNTXBioNTech SE 3.17%344.060.0%$1596.83m
NVAXNovavax, Inc. -0.92%160.4878.2%$831.00m
AMGNAmgen, Inc. 0.63%202.441.4%$596.39m
GILDGilead Sciences, Inc. -0.16%69.561.0%$505.86m
REGNRegeneron Pharmaceuticals, Inc. 0.18%635.162.7%$472.48m
VRTXVertex Pharmaceuticals, Inc. -0.31%203.811.9%$464.56m
LGVNLongeveron Inc. 11.78%20.120.0%$429.77m
ILMNIllumina, Inc. -2.85%347.283.3%$324.28m
SNSSSunesis Pharmaceuticals, Inc. -4.21%4.100.7%$286.61m
BIIBBiogen, Inc. -2.01%223.921.8%$276.52m
INCYIncyte Corp. -1.28%65.782.4%$150.25m
SGENSeagen Inc. -5.00%150.745.8%$149.09m
EXASEXACT Sciences Corp. -4.94%76.5918.0%$140.15m
OCGNOcugen, Inc. -8.72%5.760.0%$139.18m

Company Profile

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.